99 related articles for article (PubMed ID: 16184582)
1. IgA multiple myeloma responding to erythropoietin monotherapy.
Barrios M; Alliot C
Am J Hematol; 2005 Oct; 80(2):165-6. PubMed ID: 16184582
[No Abstract] [Full Text] [Related]
2. Multiple myeloma.
Bataille R; Harousseau JL
N Engl J Med; 1997 Jun; 336(23):1657-64. PubMed ID: 9171069
[No Abstract] [Full Text] [Related]
3. Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
Huston A; Brown J; Roodman GD
Exp Hematol; 2006 Dec; 34(12):1616. PubMed ID: 17157156
[No Abstract] [Full Text] [Related]
4. Deep vein thrombosis occurring on treatment of patients receiving thalidomide with erythropoietin.
Chennuru S; Baumann MA
Intern Med J; 2007 Jul; 37(7):506-7. PubMed ID: 17547733
[No Abstract] [Full Text] [Related]
5. Multiple myeloma presenting as massive ascites.
Alacacioglu L; Turgut N; Piskin O; Ali Ozcan M; Hayri Ozsan G; Demirkan F; Undar B
J BUON; 2009; 14(2):307-8. PubMed ID: 19650183
[TBL] [Abstract][Full Text] [Related]
6. [The clinical features, chemotherapy responses and survival of 223 patients with newly diagnosed multiple myeloma].
Li J; Zhao Y; Luo SK; Huang BH; Zhang GC; Peng AH; Zheng D; Su C; Xu DR; Tong XZ; Gu JL; Ding Y
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2140-3. PubMed ID: 19080477
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune haemolytic anaemia and neuropathy with IgA osteosclerotic myeloma: a case report.
Crispin PJ; Cheah PL
Pathology; 2017 Oct; 49(6):646-647. PubMed ID: 28826828
[No Abstract] [Full Text] [Related]
8. Multiple myeloma: an overview for the clinician.
Klos JR; Bortz JW
J Am Osteopath Assoc; 1979 Oct; 79(2):113-9. PubMed ID: 489441
[No Abstract] [Full Text] [Related]
9. [Apropos of a case of multiple myeloma in a 81-year-old patient].
Pellegrin B; Durand-Gasselin B; Rossignol F; Siguret V
Ann Biol Clin (Paris); 1997; 55(1):43-4. PubMed ID: 9099252
[No Abstract] [Full Text] [Related]
10. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Lonial S; Richardson PG; San Miguel J; Sonneveld P; Schuster MW; Bladé J; Cavenagh J; Rajkumar SV; Jakubowiak AJ; Esseltine DL; Anderson KC; Harousseau JL
Br J Haematol; 2008 Oct; 143(2):222-9. PubMed ID: 18713253
[TBL] [Abstract][Full Text] [Related]
11. IgA myeloma presenting as diabetes mellitus with refractory anaemia.
Basu S; Gupta N; Malhotra H
J Assoc Physicians India; 2002 Jul; 50():981-2. PubMed ID: 12126363
[No Abstract] [Full Text] [Related]
12. IgA myeloma with quadrangular crystalline inclusions.
Daneshbod Y; Kumar PV; Tabei SZ
Haematologica; 2004 Aug; 89(8):EIM18. PubMed ID: 15339699
[No Abstract] [Full Text] [Related]
13. Cast nephropathy in multiple myeloma.
Chim CS; Li FK; Chan KW
Haematologica; 2004 Apr; 89(4):EIM08. PubMed ID: 15075111
[No Abstract] [Full Text] [Related]
14. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.
Rajkumar SV; Richardson PG; Lacy MQ; Dispenzieri A; Greipp PR; Witzig TE; Schlossman R; Sidor CF; Anderson KC; Gertz MA
Clin Cancer Res; 2007 Oct; 13(20):6162-7. PubMed ID: 17947482
[TBL] [Abstract][Full Text] [Related]
15. IgA multiple myeloma presenting as non-obstructive jaundice.
Arebi N; Patel B; Aqel NM; Pitcher MC
Postgrad Med J; 2004 Aug; 80(946):489-90. PubMed ID: 15299163
[TBL] [Abstract][Full Text] [Related]
16. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
[No Abstract] [Full Text] [Related]
17. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Cibeira MT; Rosiñol L; Ramiro L; Esteve J; Torrebadell M; Bladé J
Eur J Haematol; 2006 Dec; 77(6):486-92. PubMed ID: 16978238
[TBL] [Abstract][Full Text] [Related]
18. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
Katodritou E; Gastari V; Verrou E; Hadjiaggelidou C; Varthaliti M; Georgiadou S; Laschos K; Xirou P; Yiannaki E; Constantinou N; Markala D; Zervas K
Leuk Res; 2009 Aug; 33(8):1137-40. PubMed ID: 19250676
[TBL] [Abstract][Full Text] [Related]
19. [Pulmonary involvement in IgA multiple myeloma. A case report and review of the literature].
Conesa Bernal C; Pascual Lledó F; Calvo Bonachera J
Arch Bronconeumol; 1999 Jan; 35(1):54-5. PubMed ID: 10047924
[No Abstract] [Full Text] [Related]
20. Current therapies for multiple myeloma.
Tariman JD
J Infus Nurs; 2007; 30(2):113-8; quiz 121. PubMed ID: 17413496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
